Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co Expands C Diff Franchise With US Zinplava Approval

Executive Summary

Merck & Co is planning a first-quarter 2017 launch of Zinplava, its novel therapy for use in Clostridium difficile infection, following a US FDA approval, strengthening the company’s leading position in an infectious disease with great unmet need.

You may also be interested in...



Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.

Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development

Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.

More Vaccine Disappointment For Sanofi As First C Diff Toxoid Vaccine Fails

A second dose of bad news for Sanofi's vaccines unit sees its C. difficile vaccine dropped after a Phase III study was deemed unlikely to succeed.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel